Our Team

Oliver is a highly motivated pharmaceutical professional with a proven track record in the cMP manufacturing of antibody drug conjugates (ADCs) and radiopharmaceuticals. With expertise in technical project management, stakeholder engagement, and cost-of-goods management strategies, Oliver has successfully managed projects across early to late-phase clinical manufacturing. His experience spans CDMO, CTO, and CRO management, as well as the development and optimization of manufacturing processes for antibody drug conjugates.

Oliver's career highlights include his strategic oversight of CMC activities at BioNTech, where he is currently Associate Director for ADC drug substance development. He has led the development and scale-up of ADC manufacturing processes, guided critical partnerships with CDMOs, and played an integral role in regulatory submissions, including IND, BLA, and MAA preparations. Notably, he designed and patented low-cost aggregate removal devices and process improvements that have increased process robustness while reducing costs.

With a PhD in Protein Biochemistry & Molecular Biology from the University of Canterbury, Oliver's scientific expertise is complemented by his extensive industry experience in process development, analytical method validation, and regulatory dossier preparation. He is passionate about advancing bio pharmaceutical manufacturing and optimizing processes to meet stringent regulatory standards.

Oliver's diverse professional journey has taken him across several countries, and he has been recognized for his contributions with numerous awards, including the Telix Pharmaceuticals "Global Manufacturing* award and the University of Canterbury Dean's Publication Award.